PFE:NYE-Pfizer Inc

COMMON STOCK | Drug Manufacturers - Major | NYE

Last Closing Price

USD 34.34

Change

-0.74 (-2.11)%

Market Cap

USD 0.76B

Volume

0.03B

Average Target Price

USD 46.27 (+34.73%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as Merck KGaA, Nektar Therapeutics, and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-08-23 )

Largest Industry Peers for Drug Manufacturers - Major

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BMY Bristol-Myers Squibb Company

-1.28 (-2.67%)

USD 0.83B 12.58 9.69
LLY Eli Lilly and Company

-2.10 (-1.88%)

USD 0.38B 14.08 15.69
NNVC NanoViricides, Inc

N/A

USD 0.02B N/A -1.60
CPHI China Pharma Holdings, Inc

+0.01 (+3.05%)

USD 0.01B N/A -19.53
ABBV AbbVie Inc

-1.55 (-2.30%)

USD -598,384,640.00 24.25 8.76
SNY Sanofi

+0.01 (+0.02%)

USD -677,158,912.00 21.94 -27.24
GSK GlaxoSmithKline plc

+0.21 (+0.51%)

USD -1,020,166,144.00 41.31 168.23
NVS Novartis AG

-0.56 (-0.63%)

USD -1,228,816,384.00 18.29 13.41
MRK Merck & Co., Inc

-1.78 (-2.05%)

USD -1,303,019,520.00 24.32 14.15
JNJ Johnson & Johnson

-3.54 (-2.70%)

USD -1,448,476,672.00 21.80 13.01

ETFs Containing PFE

Symbol Name Weight Mer Price(Change) Market Cap
IHE iShares U.S. Pharmaceutic.. 20.47 % 0.42 %

-3.37 (-2.40%)

USD 0.35B
GNRX VanEck Vectors Generic Dr.. 9.40 % 0.55 %

N/A

USD 3.36M
FTXH First Trust Nasdaq Pharma.. 7.22 % 0.60 %

-0.40 (-1.95%)

USD 7.40M
XLV Health Care Select Sector.. 6.31 % 0.13 %

-2.10 (-2.31%)

USD 18.43B
IYH iShares U.S. Healthcare E.. 5.82 % 0.43 %

-4.31 (-2.25%)

USD 2.16B
JHMH John Hancock Multifactor .. 5.42 % 0.46 %

-0.89 (-2.66%)

USD 0.05B
FHLC Fidelity MSCI Health Care.. 5.33 % 0.08 %

-1.03 (-2.34%)

USD 1.58B
VHT Vanguard Health Care Inde.. 5.21 % 0.10 %

-4.00 (-2.35%)

USD 9.24B
RXL ProShares Ultra Health Ca.. 5.01 % 0.95 %

-5.39 (-5.36%)

USD 0.11B
XHD:CA iShares U.S. High Dividen.. 4.97 % 0.33 %

-0.56 (-1.91%)

CAD 0.21B
XHU:CA iShares U.S. High Dividen.. 4.97 % 0.33 %

-0.53 (-2.09%)

CAD 0.08B
HDV iShares Core High Dividen.. 4.90 % 0.08 %

-2.18 (-2.34%)

USD 7.30B
HHL.U:CA 4.87 % 1.15 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 4.87 % 1.15 %

-0.15 (-2.00%)

CAD 0.33B
PJP Invesco Dynamic Pharmaceu.. 4.66 % 0.56 %

-1.40 (-2.45%)

USD 0.39B
IXJ iShares Global Healthcare.. 4.35 % 0.46 %

-1.13 (-1.85%)

USD 2.21B
XHC:CA iShares Global Healthcare.. 4.33 % 0.65 %

-1.22 (-2.52%)

CAD 0.29B
DURA VanEck Vectors Morningsta.. 4.25 % 0.00 %

-0.74 (-2.68%)

USD 9.82M
SPMO Invesco S&P 500 Momentum .. 4.11 % 0.13 %

-0.80 (-1.98%)

USD 0.06B
DJD Invesco Dow Jones Industr.. 4.07 % 0.09 %

-0.91 (-2.51%)

USD 0.06B
SCHD Schwab U.S. Dividend Equi.. 3.93 % 0.07 %

-1.42 (-2.67%)

USD 9.50B
PILL Direxion Daily Pharmaceut.. 3.90 % 0.98 %

-1.03 (-7.69%)

USD 0.01B
JKF iShares Morningstar Large.. 3.35 % 0.25 %

-2.57 (-2.42%)

USD 0.52B
RWDC Direxion MSCI Defensives .. 3.03 % 0.00 %

-1.18 (-2.32%)

USD 0.01B
XDU:CA iShares Core MSCI US Qual.. 2.91 % 0.16 %

-0.47 (-2.10%)

CAD 0.06B
XDUH:CA iShares Core MSCI US Qual.. 2.89 % 0.15 %

-0.12 (-0.55%)

CAD 0.01B
SHU:CA 2.83 % 0.70 %

N/A

N/A
VLUE 2.74 % 0.15 %

N/A

N/A
ZVU:CA BMO MSCI USA Value Index .. 2.74 % 0.33 %

N/A

CAD 8.55M
WEXP 2.66 % 0.33 %

N/A

N/A
SDGA Impact Shares Sustainable.. 2.58 % 0.00 %

-0.45 (-2.23%)

USD 1.03M
DHS WisdomTree U.S. High Divi.. 2.57 % 0.38 %

-1.67 (-2.32%)

USD 0.96B
HID:CA WisdomTree U.S. High Divi.. 2.57 % 0.40 %

N/A

CAD 3.15M
HID.B:CA 2.57 % 0.40 %

N/A

N/A
XDG:CA iShares Core MSCI Global .. 2.37 % 0.22 %

-0.37 (-1.81%)

CAD 0.09B
XDGH:CA iShares Core MSCI Global .. 2.35 % 0.22 %

-0.08 (-0.38%)

CAD 0.03B
OUSA O'Shares FTSE U.S. Qualit.. 2.33 % 0.48 %

-0.77 (-2.25%)

USD 0.50B
PEU.B:CA 2.24 % 1.16 %

N/A

N/A
DGRO iShares Core Dividend Gro.. 2.19 % 0.08 %

-0.95 (-2.49%)

USD 7.71B
VYM Vanguard High Dividend Yi.. 2.12 % 0.06 %

-2.10 (-2.44%)

USD 24.51B
FDRR Fidelity Dividend ETF for.. 1.89 % 0.30 %

-0.87 (-2.76%)

USD 0.37B
RUD:CA RBC Quant U.S. Dividend L.. 1.62 % 0.43 %

-0.76 (-2.17%)

CAD 0.39B
RUD.U:CA 1.62 % 0.43 %

N/A

N/A
SPYG SPDR Portfolio S&P 500 Gr.. 1.62 % 0.06 %

-0.97 (-2.50%)

USD 5.43B
IVW iShares S&P 500 Growth ET.. 1.62 % 0.18 %

-4.51 (-2.51%)

USD 23.46B
VOOG Vanguard S&P 500 Growth I.. 1.62 % 0.15 %

-3.95 (-2.45%)

USD 2.74B
JVAL JPMorgan U.S. Value Facto.. 1.58 % 0.12 %

-0.76 (-2.94%)

USD 0.06B
DEW WisdomTree Global High Di.. 1.57 % 0.58 %

-0.90 (-2.01%)

USD 0.09B
FQAL Fidelity Quality Factor E.. 1.56 % 0.30 %

-0.87 (-2.50%)

USD 0.16B
IUSG iShares Core S&P U.S. Gro.. 1.52 % 0.04 %

-1.62 (-2.58%)

USD 6.66B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers - Major)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.33% 20% F 11% F
Dividend Return 2.47% 56% F 66% D
Total Return -18.85% 20% F 11% F
Trailing 12 Months  
Capital Gain -18.63% 30% F 27% F
Dividend Return 3.36% 56% F 63% D
Total Return -15.26% 30% F 29% F
Trailing 5 Years  
Capital Gain 18.74% 50% F 69% D+
Dividend Return 21.78% 80% B- 73% C
Total Return 40.53% 60% D- 72% C-
Average Annual (5 Year Horizon)  
Capital Gain 7.32% 60% D- 74% C
Dividend Return 3.73% 70% C- 69% D+
Total Return 11.04% 70% C- 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 10.36% 90% A- 71% C-
Risk Adjusted Return 106.54% 100% A+ 91% A-
Market Capitalization 0.76B 92% A- 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers - Major)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.21 80% B- 55% F
Price/Book Ratio 3.28 67% D+ 26% F
Price / Cash Flow Ratio 12.26 67% D+ 35% F
EV/EBITDA 10.19 58% F 47% F
Management Effectiveness  
Return on Equity 19.49% 55% F 85% B
Return on Invested Capital 14.30% 58% F 83% B
Return on Assets 6.27% 50% F 82% B-
Debt to Equity Ratio 52.51% 45% F 63% D
Technical Ratios  
Short Ratio 2.67 50% F 50% F
Short Percent 1.22% 67% D+ 87% B+
Beta 0.37 83% B 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector